| 2.67 |  +0.10 / +3.89% |
Data as of Dec 10 | Day’s Change |
| 2.72 | +0.05 / +1.87% |
Volume: 1.0K |
| BioLineRx Presents Positive Preclinical Results of AML Treatment at ASH Dec 10 / Benzinga | Pharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook Dec 03 / Zacks.com |
| Pharma & Biotech Stock Outlook - Dec 2013 - Zacks Analyst Interviews Dec 03 / Zacks.com | New Data on BioLineRx BL-7040 - Analyst Blog Nov 27 / Zacks.com |
| Previous close | 2.57 |
| Today’s open | 2.80 |
| Day’s range | -- - -- |
| Volume | 218,090 |
| Average volume (3 months) | 100,233 |
| Market cap | $61.0M |
| Dividend yield | -- |
| Earnings growth (last year) | -- |
| Earnings growth (this year) | -- |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | -- |
| P/E ratio | -- |
| Price/Sales | -- |
| Price/Book | -- |
| Today’s change | Today’s % change | |
|---|---|---|
| ORMPOramed Pharmaceutica... | +0.05 | +0.63% |
| OPLIOphthalix Inc | 0.00 | 0.00% |
| ANTHAnthera Pharmaceutic... | +0.05 | +1.73% |
| VTUSVentrus Biosciences ... | 0.00 | 0.00% |
| Next reporting date | March 11, 2014 |
| EPS forecast (this quarter) | -$0.07 |
| Annual revenue (last year) | -- |
| Annual profit (last year) | -- |
| Net profit margin | -- |
Sector Health Technology |
Industry Pharmaceuticals: Other |
No executives to display |
Corporate headquarters --, -- |
.
